Tag Archives: bioterrorism

Assessing the United States’ Bioterrorism Preparation

NAFAC Week

By Sam Klein

While the United States funds by far the most biomedical research in the private and public sectors, its investment in this space has declined in recent years, as has its share of the total global investment.1 This decrease stands in stark contrast to the growing threat of biological weapons of mass destruction; there is “reason for concern that future bioterrorism attacks may be more effective than incidents in the past, and disease control facilities in other countries may not be as robust as those in our own.”2,3 While biological weapons research is a subset of all biological research, the downward trend in the greater field is not promising; the field must be considered holistically as epidemiology, immunology, and related subfields that can inform biological attack response even if they are not all classified as biological weapons defense research. Because the United States’ biological WMD preparedness is inadequate, the United States government should substantially increase its investment in biological weapons response, including private- and public-sector biomedical research, treatment coordination infrastructure, and intelligence-driven threat mitigation.4

Need for Research

The United States government should invest at least $155.8 billion next year in public research and private research grants, corresponding to our 2007 figure adjusted for inflation. This was the demonstrated need in 2007, and the need is at least as large now as it was ten years ago given our present state of understanding and preparedness.5

Although general epidemiological research is certainly useful in preparing for a targeted outbreak, bioterrorism research must also include more focused analysis. Biological weapons of mass destruction can be qualitatively different from naturally-occurring outbreaks of disease, both in terms of how concentrated they are and in their mode of transfer. This difference can be to the extent that a weaponized pathogen is untreatable by conventional means such as vaccination, as even a naturally occurring analog would respond to treatment.6 Aerosolizing normally grounded biohazards can render existing epidemiology models of those materials dangerously misleading, as spreading could take place at a far faster pace than expected. These factors all demonstrate the need for dedicated biological weapons research.

In addition to infecting humans, bio-WMD can also attack a population indirectly, for instance via agriculture.7 Given increasing monoculture and despeciation (i.e. biodiversity loss) in U.S. agriculture, American food supply and agricultural byproducts (e.g. ethanol) are less resilient to targeted bioterrorism.

A recent (2013) network analysis of the American interdisciplinary approach to bioterrorism research and prevention sought to determine whether the research being produced was covering the bases necessary to produce positive public health outcomes in the event of an attack. It finds value in the decentralized nature of the American approach, but also calls for more interdisciplinary research collaboration and greater “development of discovery techniques that are specialized to bioterrorism and security research sources.”8 Further investment should be channeled to these areas in addition to general epidemiology research.

Treatment Coordination Infrastructure

In 2004, the Project Bioshield Act appropriated $5 billion for preparation against likely bioweapons such as anthrax and botulism. This investment included stockpiling millions of vaccines.9 While this is a good start, momentum for this sort of investment has died down in the absence of political pressure 15 years after 9/11.

Early detection of infection is critical to saving individual lives and identifying and limiting the spread of a biological weapon of mass destruction. This will invariably happen at the local level, so it is critical that doctors on the ground across the country are knowledgeable of the symptoms of deployable biohazards and that they have the ability to quickly report incidents up the chain of command.10 It is likewise critical that the government continue to invest in bio-WMD epidemiological modeling (distinct from traditional modeling, as stated above) and in infrastructure to track ground-level reports of symptoms with the capability of distinguishing an attack from a natural outbreak (which should be treated differently).

In 2011, the Department of Health and Human Services discontinued a program that outlined a comprehensive model of epidemic response with an emphasis on bioterrorism. The model, known as the Weill/Cornell Bioterrorism and Epidemic Response Model (BERM), was used by hospitals and epidemiologists.11 It has since been supplanted by CDC guidelines for epidemic response, but extensive research fails to yield a robust replacement that affords the same flexibility as BERM with regard to bioterror-specific cases.12 The government should invest in consolidating and refining the approach and publicizing it to the necessary channels as mentioned above.

Threat Mitigation

Finally, there is little publicly known intelligence on foreign state and non-state actor bioterrorism capabilities beyond the Congressional Research Service figure that12  several countries plus the United States have or have had biological weapons research programs (if not weapons themselves).13 This intelligence is extremely limited, in part because of the concealable nature of bio-WMD development. While procurement of some dangerous biological agents can be difficult outside of visible controlled facilities, others require less effort. However, the public may lack the fear and urgency needed to motivate policymakers to invest in biological weapons threat mitigation. In 2003, Colin Powell famously held a model vial of “anthrax” to the United Nations Security Council to make the case of invasion. While the Hussein regime was in fact weaponizing biological weapons including anthrax, simultaneous failures of U.S. intelligence cast a shadow on all of the WMD intelligence.14

One of the major deterrents to weaponizing biologics is the difficulty in controlling their spread; unlike conventional weapons and other WMD, biological weapons quite literally have “lives of their own” and, once deployed, could ostensibly infect the assailant’s population. However, one could conceive of a scenario in which the assailing population has been vaccinated so that the attack only affects the intended target.15

Conclusion

Biological weapons are a clear and present danger to the United States, and the country’s understanding of and preparation for an attack are grossly inadequate. Substantial increases in biological defense research, crisis management, and threat prevention are crucial to increase the security of American citizens.

Sam Klein studies political science and writing at Washington University in St. Louis, where he also serves as executive director of the Washington University Political Review. A native of Bethesda, MD, Sam is interested in domestic legislative politics and foreign affairs. In addition to the Political Review, he is involved in Model UN and student government. He intends to graduate in 2018.

Works Cited

Barker, Gary C. “Analysis of Research Publications that Relate to Bioterrorism and Risk Assessment.” Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 11, no. 1 (2013). doi:10.1089/bsp.2013.0019.

Chakma, Justin, Gordon H. Sun, Jeffrey D. Steinberg, Stephen M. Sammut, and Reshma Jagsi. “Asia’s Ascent — Global Trends in Biomedical R&D Expenditures.” New England Journal of Medicine 370, no. 1 (2014): 3-6. doi:10.1056/nejmp1311068.

Gerstein, Daniel M. “Countering Bioterror.” RAND Corporation. January 18, 2016. Accessed March 24, 2017. http://www.rand.org/blog/2016/01/countering-bioterror.html.

“Healthcare Preparedness Capabilities.” January 2012. Accessed March 25, 2017. https://www.phe.gov/Preparedness/planning/hpp/reports/Documents/capabilities.pdf.

Henderson, Donald A. “The Looming Threat of Bioterrorism.” Science 283, no. 5406 (1999): 1279-282. doi:10.1126/science.283.5406.1279.

Hupert, Nathaniel, Jason Cuomo, and Christopher Neukermans. “The Weill/Cornell Bioterrorism and Epidemic Outbreak Response Model (BERM).” Archive: Agency for Healthcare Research Quality. September 8, 2004. Accessed March 25, 2017. https://archive.ahrq.gov/research/biomodel3/index.asp.

Jansen, H. J., F. J. Breeveld, C. Stijnis, and M. P. Grobusch. “Biological warfare, bioterrorism, and biocrime.” Clinical Microbiology and Infection 20, no. 6 (June 2014): 488-96. doi:10.1111/1469-0691.12699.

Kerr, Paul K. Nuclear, Biological, and Chemical Weapons and Missiles: Status and Trends. Report. Congressional Research Service. February 20, 2008.

Madad, Syra S. “Bioterrorism: An Emerging Global Health Threat.” Journal of Bioterrorism & Biodefense 05, no. 01 (August 4, 2014). doi:10.4172/2157-2526.1000129.

Martin, James W., George W. Christopher, and Edward M. Eitzen, Jr. “History of Biological Weapons: From Poisoned Darts to Intentional Epidemics.” In Medical Aspects of Biological Warfare, edited by Zygmunt F. Dembek. Washington, DC: Borden Institute, Walter Reed Army Medical Center, 2007.

Pifer, Steven. “Interview with Amb. Steven Pifer.” Interview by author. March 31, 2017. “The White House.” National Archives and Records Administration. July 21, 2004. Accessed

March 25, 2017. https://georgewbush-whitehouse.archives.gov/infocus/bioshield/.

Weisman, Steven R. “Powell Calls His U.N. Speech a Lasting Blot on His Record.” New York Times, September 9, 2005.

References

1. Chakma, Justin, Gordon H. Sun, Jeffrey D. Steinberg, Stephen M. Sammut, and Reshma Jagsi. “Asia’s Ascent — Global Trends in Biomedical R&D Expenditures.” New England Journal of Medicine 370, no. 1 (2014): 3-6. doi:10.1056/nejmp1311068.

2. Jansen, H. J., F. J. Breeveld, C. Stijnis, and M. P. Grobusch. “Biological warfare, bioterrorism, and biocrime.” Clinical Microbiology and Infection 20, no. 6 (June 2014): 488-96. doi:10.1111/1469-0691.12699.

3. Henderson, Donald A. “The Looming Threat of Bioterrorism.” Science 283, no. 5406 (1999): 1279-282. doi:10.1126/science.283.5406.1279.

4. Chakma et al. “Asia’s Ascent.”

5. Pifer, Steven. “Interview with Amb. Steven Pifer.” Interview by author. March 31, 2017.

6. Gerstein, Daniel M. “Countering Bioterror.” RAND Corporation. January 18, 2016. Accessed March 24, 2017. http://www.rand.org/blog/2016/01/countering-bioterror.html.

7. Martin, James W., George W. Christopher, and Edward M. Eitzen, Jr. “History of Biological Weapons: From Poisoned Darts to Intentional Epidemics.” In Medical aspects of biological warfare, edited by Zygmunt F. Dembek. Washington, DC: Borden Institute, Walter Reed Army Medical Center, 2007.

8. Barker, Gary C. “Analysis of Research Publications that Relate to Bioterrorism and Risk Assessment.” Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 11, no. 1 (2013). doi:10.1089/bsp.2013.0019.

9. “The White House.” National Archives and Records Administration. July 21, 2004. Accessed March 25, 2017. https://georgewbush-whitehouse.archives.gov/infocus/bioshield/.

10 Madad, Syra S. “Bioterrorism: An Emerging Global Health Threat.” Journal of Bioterrorism & Biodefense 05, no. 01 (August 4, 2014). doi:10.4172/2157-2526.1000129.

11. Hupert, Nathaniel, Jason Cuomo, and Christopher Neukermans. “The Weill/Cornell Bioterrorism and Epidemic Outbreak Response Model (BERM).” Archive: Agency for Healthcare Research Quality. September 8, 2004. Accessed March 25, 2017. https://archive.ahrq.gov/research/biomodel3/index.asp.

12 “Healthcare Preparedness Capabilities.” January 2012. Accessed March 25, 2017. https://www.phe.gov/Preparedness/planning/hpp/reports/Documents/capabilities.pdf.

13 Kerr, Paul K. Nuclear, Biological, and Chemical Weapons and Missiles: Status and Trends. Report. Congressional Research Service. February 20, 2008.

14 Weisman, Steven R. “Powell Calls His U.N. Speech a Lasting Blot on His Record.” New York Times, September 9, 2005.

15 Pifer, Steven. “Interview.”

Featured Image: Credit U.S. Army

How To Make The ‘Ebola Bomb’: Why You Should Stop Worrying About Bioterrorism

By Sandra Ivanov

The Ebola outbreak in West Africa is the deadliest epidemic since the virus was discovered in 1976, crossing international borders, it has claimed over 2’600 lives (as of September 18, 2014). There is no vaccine and there is no cure. Aid and medical personnel are sought from all over the world, borders have been contained, and risks of rising violent conflict continue to develop out of the Ebola eruption. However, there have been other interesting analyses of this issue on the side – media and opinion pieces are claiming that terrorist groups could get a hold of the virus and spread it around their regions, and the world (see for example Rick Noack, “Why Ebola worries the Defense Department“, The Washington Post, 05.08.2014). Well, I wanted to test this claim for myself, so with a bit of research and optimism, I’ve created a recipe to examine what a potential terrorist group would need to do to make this so-called “Ebola Bomb” – how hard could it really be?

ebola-001

Many studies from a health, as well as a humanities perspective, assume that terrorists could successfully generate biological or chemical agents and weaponise them. Taking this initial premise, a lot of literature has been based around this looming threat, subsequently offering policy advice, public health recommendations, and technological investment to avoid such catastrophes. However it would be useful to deconstruct this claim entirely. So I’ll begin by offering a baking recipe, to explore at the very core, what a group would need to do to successfully create a biological weapon, in this case, utilising the Ebola virus.

Ingredients
Firstly, any terrorist group wanting to create and weaponise a biological or chemical agent will need to have an appropriate kitchen. In the case of the Ebola virus, a standard biosafety level 4 (BSL-4) scene will be required (Adeline M. Nyamathi et al., “Ebola Virus: Immune Mechanisms of Protection and Vaccine Development“, Biological Research For Nursing 4, No. 4, April 2003: 276-281). Some features of these laboratories include decontamination mechanisms, pest management systems, air filters, and special suits. Sometimes the kitchen will have to be in a separate building, or in an isolated area within a building to meet the safety requirements. Not only will the kitchen be under strict conditions, the baking process will need to be kept in total secrecy. The constant threat of law enforcements raiding facilities, and intelligence and secret services detecting activities will have to be avoided. Also, there are only some fifty of these laboratories successfully maintained worldwide.

Before starting, make sure there is a baking dish of ‘uncertainty’ readily available to just throw all of the following ingredients into:

  • 1 Tablespoon of Proper Agent

Initially, a terrorist group must decide what kind of agent they would like to use in a bioterror attack. This is one part of the recipe which can be modified, but the other ingredients will be standard for all types of attacks. The recent spread of the deadly Ebola virus will be the agent of choice for this bomb. Ebola is a virus which is passed to humans through contact with infected animals. The spread of the virus from person-to-person is brought about through blood and bodily fluids, as well as exposure to a contaminated environment. An infected live host with Ebola would need to be maintained in a human or animal – only a few animals are able to be used as hosts, such as primates, bats, and forest antelope. Although Ebola infection of animals through aerosol particles can be effective, it has not successfully been transferred with this method to humans (Manoj Karwa, Brian Currie and Vladimir Kvetan, “Bioterrorism: Preparing for the impossible or the improbable“, Critical Care Medicine 33, No. 1, January 2005: 75-95).

  • 1 Bucket of Resources and Money

In order to develop a biological weapon, a substantial amount of material and money is required. Investment is needed from the very outset – taking into account membership size and capabilities of a terrorist group, financial assets of a group, and making sure territory and proper infrastructure is available for the biological agent. For a successful bomb to be created, a group must think about the resources they will need for each stage of the baking process, such as weapons production, potential testing phases, and logistics, such as transportation and communications technologies (Victor H. Asal, Gary A. Ackerman and R. Karl Rethemeyer, “Connections Can Be Toxic: Terrorist Organizational Factors and the Pursuit of CBRN Terrorism“, National Consortium for the Study of Terrorism and Responses to Terrorism, 2006). Resources needed for an “Ebola Bomb” will most likely need to be imported from the outside, and a group must determine the feasibility of acquiring the materials and technologies needed for the bomb (Jean Pascal Zanders, “Assessing the risk of chemical and biological weapons proliferation to terrorists“, The Nonproliferation Review, Fall 1999: 17-34). A surplus of money would also be a smart idea in case technical difficulties arise.

  • 5 Cups of Expertise

With all the correct resources and necessary amount of monetary support, the recipe will require the right kind of know-how. For an operation like this, a terrorist group should have members with high levels of education and training in science, engineering, and technological development, to deal with highly virulent agents, and for successful weaponisation (Zanders). A group may need to be integrated into knowledge flows and institutions, or be able to recruit members to their cause with this specific expertise (Asal, Ackerman and Rethemeyer). Knowledge and expertise is required to create the correct strain, handling the agent, growing the agent with the desired characteristics, and maintaining the agent. Taking Ebola specifically requires synthesising proteins which make it infectious, and becomes a task that is difficult and unlikely to succeed (Amanda M. Teckma, “The Bioterrorist Threat of Ebola in East Africa and Implications for Global
Health and Security
“, Global Policy Essay, May 2013). If Ebola is successfully created in the kitchen, it is not itself a biological weapon – an expert will be required to transform the virus into a workable mechanism for dissemination.

  • A Teaspoon of Risk

The decision to use biological weapons for an attack is in itself extremely risky. There is a risk that bioterrorism could cause dissenting views among followers, and that public approval and opinion may channel the way a group operates. After all, terrorists are political communicators, wanting to bring attention to their grievances. If a group becomes polarised or resented by their actions, they will not see the benefits of pursuing certain methods. Terrorists want to send powerful messages, gain more members, in which these members assist to bring about certain plans and demands. Therefore, public opinion and political opportunism will be risked in a quest to create a bioweapon such as an “Ebola Bomb” (Zanders). Secondly, a terrorist group may be subject to more scrutiny or attention. This is why keeping activities covert will be a key to success. States will be more vigilant towards groups that are known to be seeking and acquiring biological and chemical capabilities (Asal, Ackerman and Rethemeyer). And finally, risk will always cling on to funding requirements, and potential technical difficulties in all stages of the bioweapon making process.

  • A Fist of Time

Now this recipe is going to take a while to prepare and bake in the oven, and there is no particular moment to determine when it should be removed from the baking dish. So, whatever group wants to make this bomb, will need to realise this is a long-term and complex effort. It will not work like most conventional weapons, which produce a high number of casualties with a single explosion, and that could be a reason why bioterrorism is not the most popular means for a violent attack – demanding time, effort, and resources without guarantees of a concrete result. A fist full of time may be needed so that knowledge, both tacit and explicit, can be acquired, as well as accounting for the various mistakes and learning curves to overcome (Asal, Ackerman and Rethemeyer). It can also refer to how long it will take to cook up, maintain and prepare a virus for an attack. It will take time to create a successful weapon with prior testing, and wait for the correct environmental conditions when it comes to dissemination. Time will have to be a group investment – it is not the kind of bomb that will detonate immediately.

  • A Pinch of Curiosity of the Unknown

The teaspoon of risk coincides with uncertainty, and there will need to be a commitment to potential unknown factors. It is unknown what will happen once a virus is disseminated. Will the weapon even work in the first place? Weather conditions are unpredictable and Ebola will not have a prominent effect in certain environments. What happens to the terrorist group if the attack fails? What happens to the reputation of the group and its membership, or will the group cease to exist? If the recipe is a success, it is impossible to control the biological agent which is released – not only can it affect the targeted population, but it may annihilate the terrorist group itself. There will be an unknown into potentially losing local and international support, and donors if this causes widespread catastrophe.

Scientists from the Southern African Development Community region, including a sponsored postdoctoral research fellow by the Southern African Centre for Infectious Disease Surveillance, working in the only biosafety level 4 (BSL-4) laboratory in Africa, which is located at the National Institute for Communicable Diseases, Johannesburg, South Africa.
Scientists from the Southern African Development Community region, including a sponsored postdoctoral research fellow by the Southern African Centre for Infectious Disease Surveillance, working in the only biosafety level 4 (BSL-4) laboratory in Africa, which is located at the National Institute for Communicable Diseases, Johannesburg, South Africa.

Method: Weaponisation and Dissemination
Mix that up good in your baking dish of what is now “deep uncertainty” and pop it in the oven to bake. But as time passes, it seems as though the ingredients are not rising. The process of turning a biological agent into a weapon for attack is the phase with the most hurdles for terrorist groups. In order for a virus to inflict a lot of harm, it has to be disseminated through an effective delivery mechanism. As mentioned previously, the Ebola virus needs a live host. Weaponising a live host is more difficult than other agents which can be cultured on dishes of nutrients. The process has many stages which involve testing, refining, upgrading, and toughening. The methods to disseminate an agent are only known to few people, and rarely published – it is not a basement project (Teckman).

Let’s take Aum Shinrikyo as an example of conducting a bioterrorist attack (even it was “only” a chemical attack). This apocalyptic religious organisation in Japan managed to release sarin gas inside a Tokyo subway, killing a dozen people, and injuring 50. However, even with money and resources, they failed to effectively weaponise the chemical. Factors which led to their failure included internal secrecy and breakdown in communication; selecting members only solely dedicated to their cause to work on the weapons, ultimately employing unskilled people to operate and maintain the project, causing accidents and leaks (Zanders). Aum Shinrikyo’s attempt to disseminate botulinum toxin into Tokyo using a truck with a compressor and vents, did not work because they had not acquired an infectious strain (Sharon Begley, “Unmasking Bioterror“, Newsweek, 13.03.2010; “Chronology of Aum Shinrikyo’s CBW Activities“, Monterey Institute of International Studies, 2001). Finally, a major obstacle to successfully disseminating Ebola, is because this virus requires a specific environment in order to thrive. Weather conditions can be unpredictable, and Ebola particularly needs high temperatures and humidity to remain effective.

The emergency service tend to victims of the Aum Shinrikyo sarin attack on Tokyo's subway in 1995 (Photo: Rex Features).
The emergency service tend to victims of the Aum Shinrikyo sarin attack on Tokyo’s subway in 1995 (Photo: Rex Features).

Decoration: Results and Conclusions
Obviously, this “Ebola Bomb” has not come close to containing the right requirements needed to explode. Looking back historically, pathogens, and all kinds of toxins have been used as tools in sabotage and assassinations since the beginning of time. Now, it would be silly to say this recipe will never work – there will always be a possibility that Ebola or other viruses may be used as biological weapons in the future. However, the likelihood of its development and use by a terrorist group is quite improbable.

Mentioning Aum Shinrikyo again, they are an organisation which at the time, had a war chest of more than $300 million, with six laboratories and a handful of biologists, in the end having insurmountable difficulties with the weaponisation and dissemination processes, and killing a dozen people (Begley). There is a greater amount of knowledge and technology available in our day and age than in 1995 with the Aum Shinrikyo attacks, but it is still unlikely that this will be the weapon of choice. Examining state biological weapons programmes, Soviet Russia had almost 60,000 personnel employed in their weapons development, with only about 100 people that actually knew how to take an agent through the full production process. In the United States, at Fort Detrick, there were 250 buildings with 3,000 personnel, and it took them a while to weaponise a single agent, such as botulinum (Manoj Karwa, Brian Currie and Vladimir Kvetan).

Nowadays, the narrative has assumed a worst case scenario analysis, and subsequently narrowed down bioterrorism to a single threat prognosis. There is little distinction made between what is conceivable and possible, and what is likely in terms of bioterrorism. Anything can be conceived as a terrorist threat, but what is the reality? The “Ebola Bomb” is not a danger. The likelihood of a bioterrorist attack remains highly unlikely (Teckman). The focus should be on preventing natural pandemics of human disease, such as tuberculosis, SARS, AIDS and influenza – emphasis placed on how we can cure diseases, and how medical training could be improved to contain, and avoid viruses such as Ebola altogether. Resources are being pumped into biodefence in the security as well as the medical sector, but preparedness and investment in bioterrorism needs to be in proportion to actual threats, otherwise, funds are diverted away from much needed public health programmes:

Diversion of resources from public health in the United States include diversion of funds needed for protection against other chemical risks – spills, leaks and explosives – and infectious diseases. Each year in the United States there are 60,000 chemical spills, leaks and explosions, of which 8,000 are classified as ‘serious’, with over 300 deaths. There are 76 million episodes of food-borne illness, leading to 325,000 hospitalisations and 5,000 deaths, most of which could be prevented. There are 110,000 hospitalisations and 20,000 deaths from influenza, a largely preventable illness, and there are 40,000 new cases and 10,000 deaths from HIV/AIDS. Diversion of resources for public health outside the US reduce the resources that can help provide protection against diseases rooted in poverty, ignorance and absence of services. — Victor W Sidel, “Bioterrorism in the United States: A balanced assessment of risk and response“, Medicine, Conflict and Survival 19, No. 4, 2003: 318-325.

The effectiveness of biological weapons has never been clearly shown, the numbers of casualties have been small and it is likely that hoaxes and false alarms in the future will continue to outnumber real events and create disruptive hysteria (Manoj Karwa, Brian Currie and Vladimir Kvetan). Emphasis needs to be back on medical research, as well as social science investigations into the roots of why terrorist groups would even want to pursue biological weapons, and the lengths they would go to use them. Let this be an avenue for further pondering and exploring, the realities of bioterrorism.

Sandra Ivanov is from New Zealand with a postgraduate education in Peace and Conflict Studies. She is currently an editor of the blog “Conflict and Security“, and primarily works in the non-government sector. You can find her through Linkedin or follow her updates on Twitter.